Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2024-03-04 00:00:00 ET · period of report 2024-03-01 · accession 0000950170-24-025083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-04 | 2024-03-04 | KYMR | Jacobs Bruce N. | CFO | S - Sale | $41.85 | -3,934 | 143.9K | -3% | -$164.7K |
| D | 2024-03-04 | 2024-03-01 | KYMR | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +31.2K | 146.3K | +27% | $0 |
| D | 2024-03-04 | 2024-03-01 | KYMR | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +187.5K | 187.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-04 | S | D | 255 | $43.26 | 142,351 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-03-04 | S | D | 1,301 | $42.39 | 142,606 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2024-03-04 | S | D | 2,378 | $41.41 | 143,907 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2024-03-01 | A | A | 31,250 | $0.00 | 146,285 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-03-01 | A | A | 187,500 | $0.00 | 187,500 | D | $43.50 · — to 2034-02-28 | 187,500 Common Stock | (F6) The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. |